Loading
Journal of Clinical Cardiology
ISSN: 2694-5088
Late ECG Changes after Cisplatin-Based Chemotherapy in Testicular Cancer Survivors
Introducing cisplatin-based therapy into testicular cancer treatment represents a substantial progress in therapy leading to a longer survival of patients and less adverse effects; currently it represents the standard therapy.
J Clin Cardiol, 2022, Volume 3, Issue 1, p1-11 | DOI: 10.33696/cardiology.3.027The Novel Antiplatelet Agent Revacept in Cardiovascular Medicine: The Promise of Efficacy Without Bleeding
Revacept, a dimeric fusion protein of the extracellular domain of GPVI and the human Fc-fragment, inhibits collagen-mediated platelet adhesion and subsequent aggregation at the site of vascular injury. Finally, the possible utility of this pharmacological approach in the prevention of tumor metastasis is discussed.
J Clin Cardiol, 2022, Volume 3, Issue 1, p12-20 | DOI: 10.33696/cardiology.3.028Should we Target Myostatin, PCSK9 or Their Combination in Ischemia or Reperfusion Injury?
Ischemia/reperfusion (I/R) injury is the consequence of a transient interruption of the blood supply for pathologic, traumatic or surgical reasons, followed by flow restoration with rapid hemodynamic changes in the downstream tissues and organs.
J Clin Cardiol, 2022, Volume 3, Issue 1, p21-24 | DOI: 10.33696/cardiology.3.029COVID-19 Delays Presentation and Management of Acute Coronary Syndrome
The COVID-19 pandemic started at the end of 2019 and remains carrying a health threat and significant economic consequences. Over the last two years, COVID-19 has been the main Public Health issue, and has impacted regular healthcare systems, with significant build-up of waiting lists and delay in optimum management of other serious medical conditions including heart diseases and cancer.
J Clin Cardiol, 2022, Volume 3, Issue 1, p25-28 | DOI: 10.33696/cardiology.3.030Commentary on: Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?
Pulmonary Arterial Hypertension (PAH) represents a rare but devastating disease due to small pulmonary arterial vessels remodelling and increased pulmonary vascular resistance leading to right ventricular dysfunction, right heart failure and death.
J Clin Cardiol, 2022, Volume 3, Issue 1, p29-34 | DOI: 10.33696/cardiology.3.031Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.